APLS(Delisted)
Apellis (APLS) Stock Statistics, Valuation & Financial Metrics
Total Valuation
Apellis market cap is -- and enterprise value is --.
Share Statistics
Apellis has 128.02M shares outstanding, with a free float of 88.63M.
Valuation Ratios
Apellis's PE ratio is --, PB ratio is --, and PS ratio is --, showing whether the stock looks expensive or cheap.
Liquidity
Apellis's current ratio is 3.63, quick ratio is 3.16, and cash ratio is 1.43, showing its short-term liquidity position.
Return on Capital
Apellis's ROE is 46.02%, ROA is 14.10%, and ROIC is 21.95%, showing its return on capital profile.
Profitability
Apellis gross margin is 90.19%, operating margin is 14.95%, and net margin is 12.06%.
Cost Structure
Apellis spends 25.91% of revenue on R&D and 49.33% on SG&A.
Operating Efficiency
Apellis's asset turnover is 1.17, inventory turnover is 1.01, and receivables turnover is 3.27, indicating its operating efficiency.
Income Statement
Apellis's revenue is 1.11B, gross profit is 996.86M, net income is 133.27M, and EBITDA is 164.19M.
Balance Sheet
Apellis's total debt is 455.99M, net debt is 50.78M, total equity is 414.92M, and cash is 405.21M.
Cash Flow Statement
Apellis's operating cash flow is 37.77M, free cash flow is 37.47M, and CapEx is --.
Dividends & Yields
Apellis dividend yield is --, with a payout ratio of -- and dividend per share of --.
Analyst Rating
Apellis's latest analyst rating is Unrate, with an analyst target price of --.
Company Info
A commercial-stage biopharmaceutical company focused on the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade
Per Share Metrics
Apellis's EPS is 1.07, book value per share is 3.24, and free cash flow per share is 0.3.
